BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
13 Junio 2024 - 6:41PM
Business Wire
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global
oncology company, and NewBridge Pharmaceuticals have jointly
decided to conclude their partnership. This strategic decision
aligns with BeiGene’s goals to expand its presence and directly
manage operations in the MENA region.
The collaboration between the two companies began in 2020 and
included sales, distribution, and commercialization activities for
BRUKINSA® (Zanubrutinib) in the MENA region. As a result of the
partnership, BRUKINSA has been approved by the health authorities
in multiple territories and is currently marketed in several
regions with additional approvals to come. The separation is well
planned, with timelines determined on a country-by-country basis
starting in June 2024 and completing by March 31, 2025. Whilst the
distribution agreement has been agreed by the parties to terminate
on March 31, 2025, all customer-facing activities will be taken
over by BeiGene from June 11, 2024, including Medical Affairs,
Commercial Operations and Market Access, with BeiGene utilizing the
expanded team it is building in the region.
“NewBridge Pharmaceuticals has been an important enabler of our
journey in the MENA region over the past five years, and we are
grateful for their collaboration,” said Mohammed Al-Kapany, General
Manager of the MENA region. “As we conclude this partnership,
BeiGene remains committed to seamlessly transitioning to a direct
operating model across the region, reinforcing our commitment to
advancing cancer care and making our innovative treatments more
accessible to patients. We look forward to building on the
foundation laid during this time and advancing our global growth
objectives.”
Hisham El Sayed, Executive VP & Regional Head of Commercial,
Middle East & Africa for NewBridge Pharmaceuticals, commented,
“Working with BeiGene has been a rewarding journey, and we are
proud of what we have accomplished together. We support BeiGene’s
strategic decision and are committed to ensuring a seamless
transition for the healthcare providers and patients we serve.”
This strategic shift represents a significant milestone for
BeiGene as it expands its global presence. By 2025, the company
aims to achieve groundbreaking advancements in the treatment of
solid tumors and hematological cancers, reinforcing its dedication
to providing cutting-edge cancer therapies worldwide. This move
underscores BeiGene's commitment to delivering innovative and
transformative treatments to cancer patients globally.
About BeiGene
BeiGene is a global oncology company that is discovering and
developing innovative oncology treatments that are more affordable
and accessible to cancer patients worldwide. With a broad
portfolio, we are expediting development of our diverse pipeline of
novel therapeutics through our internal capabilities and
collaborations. We are committed to radically improving access to
medicines for far more patients who need them. Our growing global
team of more than 10,000 colleagues spans five continents. To learn
more about BeiGene, , please visit www.beigene.com and follow us on
LinkedIn, X (formerly known as Twitter), and Facebook.
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals is a regional specialty company with a
comprehensive pharmaceutical platform of services and expertise,
established to bridge the access gap and partner with global pharma
and biotech companies to in-license and commercialize U.S. Food and
Drug Administration or European Medicines Agency approved
innovative therapeutics that address unmet medical needs into the
Middle East and North Africa (MENA) regions.
For more information, please visit www.nbpharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240613697053/en/
For media inquiries contact - BeiGene: Louise Carter
Email: louise.carter@beigene.com Rosa Soto Email:
rosa.soto@beigene.com For media inquiries contact – NewBridge
Pharmaceuticals: Misan Abu Rmaileh Email:
misan.aburmaileh@nbpharma.com Vanessa Edmunds Email:
vanessa.edmunds@nbpharma.com
BeiGene (NASDAQ:BGNE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BeiGene (NASDAQ:BGNE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024